Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Breakthrough Bleeds Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support ICD-10 Codes for Rare Bleeding Disorders
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
Glanzmann's Thrombasthenia
Glanzmann's Thrombasthenia
  • Overview
  • Diagnosing
  • Diagnostic Algorithm

Learning the signs is the first step toward recognizing Glanzmann’s thrombasthenia

Learning the signs is the first step toward recognizing Glanzmann’s thrombasthenia

Actor portrayal

learningthe signs

Glanzmann’s thrombasthenia (GT) is a rare bleeding disorder characterized by impaired platelet function. Patients may experience symptoms ranging from minimal bruising to potentially fatal hemorrhages. Glanzmann’s thrombasthenia shares symptoms with other bleeding disorders, making diagnosis difficult.1-4

GT: a rare bleeding disorder that’s challenging to diagnose

Extremely
rare

Only approximately 1 in 1 million people are affected by GT1

Difficult to
diagnose

Similar symptoms as other acquired platelet disorders and vWD3,4

Diverse patient population

GT affects both males and females, often without a diagnosed family history5

vWD=von Willebrand disease

GT is caused by defects in the GPIIb/IIIa receptor on platelets6

  • GPIIb/IIIa, a receptor on the platelet surface, mediates platelet aggregation6
  • GPIIb/IIIa is decreased or dysfunctional in patients with GT6
  • As a result, platelet plugs do not form effectively during vessel injury, leading to lengthy episodes of bleeding6

When do GT patients experience their first bleed symptoms?

53% of GT patients experience their first bleed symptom by age 1 6,a
85% of GT patients experience their first bleed symptom by age 14 6,a

aBased on data from Glanzmann’s Thrombasthenia Registry (GTR).

GT patients’ bleeds can be severe

Most patients with Glanzmann’s thrombasthenia present with spontaneous and moderate bleeds. However, ~26% of bleeds in GT patients are severe.7,b

Severity of bleeding episodes

Types of bleeding episodes

Severity of GT patients' bleeds

Types of bleeding episodes

Types of GT patients’ bleeds

Learn how to spot the signs of Glanzmann’s thrombasthenia

Review the common signs and symptoms of Glanzmann’s thrombasthenia and see how patients typically present with this rare bleeding disorder.

Learn about diagnosing
Magnifying glass, blood droplet, and person icon

References:

  1. Di Minno G, Coppola A, Di Minno MND, et al. Glanzmann’s thrombasthenia (defective platelet integrin alpha(IIb)-beta(3)): proposals for management between evidence and open issues. Thromb Haemost. 2009;102(6):1157-1164.
  2. Nurden AT, Pillois X, Nurden P. Understanding the genetic basis of Glanzmann thrombasthenia: implications for treatment. Exp Rev Hematol. 2012;5(5):487-503
  3. Solh T, Botsford A, Solh M. Glanzmann’s thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options. J Blood Med. 2015;6:219-227.
  4. Lambert MP. What to do when you suspect an inherited platelet disorder. Hematology Am Soc Hematol Educ Program. 2011;2011:377-383.
  5. Sharathkumar AA, Shapiro AD. Platelet Function Disorders. 2nd ed. Montréal, Québec, Canada: World Federation of Hemophilia; 2008.
  6. Poon MC, Di Minno G, d’Oiron R, et al. New insights into the treatment of Glanzmann thrombasthenia. Transfus Med Rev. 2016;30(2):92-99.
  7. Di Minno G, Zotz RB, d’Oiron R, et al. The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia. Haematologica. 2015;100(8):1031-1037.
Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Breakthrough Bleeds
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support
      ICD-10 Codes for Rare Bleeding Disorders

novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to pro.novonordisk.com.

Terms of Use | Privacy Notice | Consumer Health Privacy Notice | Cookie Notice | Privacy Request | Contact Us |
novonordisk-us.com    
© 2023 Novo Nordisk All rights reserved. US23HCP00056 August 2023

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials